Literature DB >> 10533803

Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients.

E Giannini1, P Ceppa, F Botta, A Fasoli, P Romagnoli, E Cresta, V Venturino, D Risso, G Celle, R Testa.   

Abstract

BACKGROUND/AIMS: Hepatitis C virus (HCV) related disease follows a long, benign course and most affected patients have mild disease. Liver biopsy is mandatory to grade and stage the disease. Characteristic, though non-specific, HCV histological lesions such as bile duct damage and steatosis have been singled out but their association with non-histological parameters has not been completely defined. Our aim was to study the relationships among these histological lesions and clinical, biochemical, functional and virological characteristics in a group of Northern Italian patients with chronic hepatitis.
METHODS: We studied 172 patients with HCV-related chronic hepatitis. Patients were divided into groups on the basis of histology including bile duct damage and steatosis. Clinical, biochemical, functional and virological profiles were related to histological findings.
RESULTS: Histological grading and staging of disease increased as the age of patients increased. Steatosis was present in 70% of our patients and was related to a higher degree of fibrosis and to decreased functional activity. The prevalence of bile duct damage was 20%. This lesion was present in older patients with higher staging and impaired liver function. Biochemically it was associated with an increase in aspartate aminotransferase, gammaglutamyltranspeptidase, alkaline phosphatase, and total bilirubin.
CONCLUSIONS: In the population we studied, HCV chronic hepatitis was predominantly a mild disease. Moreover both steatosis and bile duct damage were also mild. Steatosis was associated with fibrosis and this might influence liver metabolic function. Bile duct lesions were found in older patients with advanced disease showing biochemical evidence ofcholestasis. The molecular role HCV might play in the pathogenesis of these histological features should be addressed in further studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533803     DOI: 10.1111/j.1478-3231.1999.tb00074.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  13 in total

1.  Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.

Authors:  Ke-Qin Hu; Sue L Currie; Hui Shen; Ramsey C Cheung; Samuel B Ho; Edmund J Bini; John D McCracken; Tim Morgan; Norbert Bräu; Warren N Schmidt; Lennox Jeffers; Teresa L Wright
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

2.  Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B.

Authors:  Ruijie Wan; Huimin Liu; Xianbo Wang; Gang Wan; Xiaojing Wang; Guiqin Zhou; Yuyong Jiang; Fengxia Sun; Zhiyun Yang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature.

Authors:  K S Kumar; M H Saboorian; W M Lee
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies.

Authors:  Gabor Lendvai; Katalin Jármay; Gizella Karácsony; Tünde Halász; Ilona Kovalszky; Kornélia Baghy; Tibor Wittmann; Zsuzsa Schaff; András Kiss
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

5.  Changes in lipid metabolism in chronic hepatitis C.

Authors:  Katalin Jármay; Gizella Karácsony; András Nagy; Zsuzsa Schaff
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

6.  A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease.

Authors:  P Sorrentino; G Tarantino; A Perrella; P Micheli; O Perrella; P Conca
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

7.  Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B.

Authors:  Sheng-di Wu; Yan-Jun Ni; Li-Li Liu; Hai Li; Lun-Gen Lu; Ji-Yao Wang
Journal:  Hepatol Int       Date:  2011-12-10       Impact factor: 6.047

8.  Construction of HCV-core gene vector and its expression in cholangiocarcinoma.

Authors:  Xiao-Fang Liu; Sheng-Quan Zou; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

9.  Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

Authors:  G Esmat; Wafaa El Akel; M Metwally; A Soliman; W Doss; M Abdel Hamid; M Kamal; K Zalata; H Khattab; M El-Kassas; M Esmat; A Hasan; M El-Raziky
Journal:  Indian J Gastroenterol       Date:  2009-08-21

10.  The Serum Gamma Glutamyl Transpeptidase - A Non invasive Diagnostic Bio Marker of Chronic Anicteric Non Alcoholic Liver Diseases.

Authors:  Krishnamurthy H A
Journal:  J Clin Diagn Res       Date:  2013-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.